In the present study, the observed reduction in ALT in the ALT ≥ 25 IU/L group may reflect improvements in hepatic steatosis and inflammation, as suggested by both preclinical studies and recent clinical trials reporting decreases in Fib-4 following imeglimin therapy [24,25]. The gene discussed is GPT; the disease is fatty liver disease.